Takeda Pharmaceutical (TAK) Cost of Revenue (2017 - 2026)

Takeda Pharmaceutical has reported Cost of Revenue for 10 years, with the latest figure at $2.6 billion in Q2 2026.

• On a quarterly basis, Cost of Revenue fell 4.03% year-over-year to $2.6 billion in Q2 2026; TTM through Jun 2026 was $15.9 billion, a 1.07% increase from a year earlier, with the FY2026 full-year figure at $10.0 billion, down 3.4% from the prior year.
• Cost of Revenue was $2.6 billion for Q2 2026 at Takeda Pharmaceutical, down from $2.6 billion in the prior quarter.
• The five-year high for Cost of Revenue was $8.1 billion in Q3 2025, with the low at $2.2 billion in Q3 2022.
• Average Cost of Revenue over 5 years is $3.4 billion, with a median of $2.5 billion recorded in 2025.
• The sharpest annual moves came in 2022 and 2023: Cost of Revenue decreased 11.72% in 2022, then surged 226.94% in 2023.
• Over 5 years, Cost of Revenue stood at $2.4 billion in 2022, then rose by 8.81% to $2.6 billion in 2023, then fell by 2.77% to $2.5 billion in 2024, then gained by 4.78% to $2.6 billion in 2025, then decreased by 3.21% to $2.6 billion in 2026.
• The last three Cost of Revenue figures came in at $2.6 billion (Q2 2026), $2.6 billion (Q1 2026), and $2.6 billion (Q4 2025), per Business Quant data.